Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PX119
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PX119 is a multi-specific biologic molecule developed by Proteologix (now part of Johnson & Johnson) for the treatment of autoimmune/inflammatory diseases and oncology indications. It has demonstrated superior potency in killing target cells with reduced side effects compared to existing antibody therapies in preclinical studies, potentially offering improved efficacy in conditions affecting large patient populations such as dermatitis and cancers. The exact mechanism, target, and structural details remain undisclosed in available sources, positioning it as an emerging candidate in the multi-specific antibody space.
Beyond the preview
Go deeper on PX119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PX119.